Plain-English translation of NCT06827899 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of drugs—venetoclax, chidaniline, and azacitidine, followed by decitabine and other medications—can help treat acute myeloid leukemia (AML), a serious blood cancer, in older adults who are newly diagnosed. The study is designed for patients aged 60 and older who either cannot tolerate or prefer not to receive standard chemotherapy treatments. Researchers want to see if this medication combination can help control the cancer and improve survival.
Acute myeloid leukemia is a serious blood cancer, and older adults often cannot tolerate the standard, intense chemotherapy treatments used for younger patients. This trial exists to find a gentler but still effective treatment option for elderly patients with newly diagnosed AML who need alternatives to traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the medication combination in two phases: first the initial drug combination (venetoclax, chidaniline, and azacitidine), followed by the second phase with decitabine and other medications. You will visit the hospital or clinic multiple times for treatment administration, blood tests, and monitoring of how well the medication is working and any side effects you experience. The exact schedule and duration will depend on how your body responds to the treatment, but you should expect regular visits and blood work throughout your participation.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Xiamen University
Collaborators
Fujian Provincial Hospital, Fujian Cancer Hospital
Enrollment target
~66 participants
Started
July 2022
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
60 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bing Xu
The First Aiffiliated hosptical of xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.